5-hydroxytryptamine receptors (serotonin receptors , 5-HT receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels found in the central and peripheral nervous systems [1, 2]. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand.
The serotonergic system is a target of many widely prescribed drugs including atypical anti-psychotics, anti-migraine medications, anxiolytics and anti-depressants [3]. However, clinical use of several serotonergic drugs caused unexpected side effects arising from off-target interactions with 5-HT receptor subtypes [4-6].
OTAVAchemicals offers 5-HT1B Receptor Targeted Library (558 compounds in total) designed with receptor-based virtual screening of pre-filtered compound library* docked in orthosteric and extended pockets of the 5-HT1B ligand binding site. The library is specifically targeted towards 5-HT1B receptor in such a way to minimize cross-reactivity with 5-HT2B receptor. This has been achieved by inspection of active site’s critical structural determinants for ligand recognition, validation of reference set of 26 known 5-HT antagonists and exclusion of predicted 5-HT2B binders from the final set of compounds by similarity analysis and docking score cut-off filtering. This library provides an excellent basis for designing subtype-selective serotonergic drugs.
* for increasing the potential for BBB penetration, the library falls into the following physicochemical property ranges: nHD < 3; PSA < 90; MolWeight < 450; CLogP 2-5; LogD 2-5
The summary of the OTAVAchemicals 5-HT1B Receptor Targeted Library characteristics:
Parameter |
Value |
Average |
MW |
< 450 |
380.8 |
CLogP |
2-5 |
3.6 |
LogD |
2-5 |
3.4 |
Number of H Donors |
≤ 3 |
1.1 |
Number of H Acceptors |
≤ 9 |
3.9 |
PSA |
< 90 |
66.0 |
Number of Rings |
> 0 |
3.7 |
Compounds with "undesirable" functionalities |
Removed |
|
Compound in 5-HT1B ligand binding site. Complex obtained with flexible docking.
All compounds are in stock, cherry-picking is available.
The library (DB, SD, XLS, PDF format) as well as the price-list is available on request. Feel free to contact us or use on-line form below to send an inquiry if you are interested to obtain this library or if you need more information.
-
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacol. Rev. 46 (2): 157–203. PMID 7938165.
-
Frazer A, Hensler JG (1999). "Chapter 13: Serotonin Receptors". In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. Philadelphia: Lippincott-Raven. pp. 263–292. ISBN 0-397-51820-X. Retrieved 2008-04-11.
-
M. Berger, J. A. Gray, B. L. Roth, The expanded biology of serotonin. Annu. Rev. Med. 60, 355 (2009). doi:10.1146/annurev.med.60.042307.110802.
-
B. L. Roth, D. J. Sheffler, W. K. Kroeze, Magic shotguns versus mag-ic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353 (2004). doi:10.1038/nrd1346 Medline.
-
J. Besnard et al., Automated design of ligands to polypharmacological profiles. Nature 492, 215 (2012). doi:10.1038/nature11691 Medline
-
B. L. Roth, Drugs and valvular heart disease. N. Engl. J. Med. 356, 6 (2007). doi:10.1056/NEJMp068265 Medline.
|